^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:HPN-217 (CD3 agonist, BCMA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Harpoon Therap Press Release
    Title:

    HARPOON THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR HPN217

    Published date:
    03/02/2022
    Excerpt:
    Harpoon Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC®, for the treatment of patients with relapsed, refractory multiple myeloma (RRMM) who have received at least four lines of therapy.